Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded at Piper Sandler

Piper Sandler upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a neutral rating to an overweight rating in a research note published on Thursday morning, Marketbeat Ratings reports. The brokerage currently has $65.00 target price on the specialty pharmaceutical company’s stock, up from their previous target price of $40.00.

A number of other equities analysts have also weighed in on the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday. Zacks Research raised Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, September 17th. Cantor Fitzgerald increased their price target on Supernus Pharmaceuticals from $46.00 to $63.00 and gave the company an “overweight” rating in a research note on Tuesday, September 30th. Finally, Wall Street Zen lowered Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, October 3rd. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, Supernus Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $64.00.

Supernus Pharmaceuticals Stock Down 1.0%

NASDAQ SUPN opened at $49.00 on Thursday. The firm has a market cap of $2.75 billion, a price-to-earnings ratio of 42.61 and a beta of 0.78. The business has a 50-day moving average price of $44.96 and a 200-day moving average price of $36.70. Supernus Pharmaceuticals has a twelve month low of $29.16 and a twelve month high of $51.78.

Insider Buying and Selling at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, CEO Jack A. Khattar sold 59,900 shares of the company’s stock in a transaction that occurred on Thursday, October 9th. The stock was sold at an average price of $50.57, for a total transaction of $3,029,143.00. Following the sale, the chief executive officer directly owned 1,206,578 shares in the company, valued at $61,016,649.46. This represents a 4.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Frank Mottola sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $45.87, for a total value of $229,350.00. Following the sale, the senior vice president owned 15,496 shares in the company, valued at approximately $710,801.52. This trade represents a 24.40% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 362,741 shares of company stock worth $16,390,592 over the last ninety days. Company insiders own 8.80% of the company’s stock.

Institutional Investors Weigh In On Supernus Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SUPN. Caitong International Asset Management Co. Ltd purchased a new stake in Supernus Pharmaceuticals during the first quarter valued at approximately $41,000. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in shares of Supernus Pharmaceuticals in the first quarter worth approximately $46,000. USA Financial Formulas purchased a new stake in shares of Supernus Pharmaceuticals in the third quarter worth approximately $50,000. EverSource Wealth Advisors LLC purchased a new stake in shares of Supernus Pharmaceuticals in the second quarter worth approximately $51,000. Finally, Raymond James Financial Inc. purchased a new stake in shares of Supernus Pharmaceuticals in the second quarter worth approximately $55,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.